Dr. Beaven is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2100 Erwin Rd
Durham, NC 27705Phone+1 919-684-8111Fax+1 919-966-6735
Summary
- Dr. Beaven cares for patients with all types of lymphoma, with a particular interest in T cell lymphoma. Along with Dr. Edith Bowers in dermatology, she runs a multidisciplinary Cutaneous lymphoma clinic.(https://unclineberger.org/patientcare/programs/lymphoma/cutaneous)
Her main area of research is the development of CarT clinical trials. The CD30 CarT trials are for patients with relapsed/refractory CD30+ lymphomas, which include Hodgkin lymphoma as well as some systemic T cell lymphomas such as anaplastic large cell lymphoma, and some cutaneous T cell lymphomas. In the near future they plan to open trials in both indolent and aggressive B cell lymphomas as well.
https://unclineberger.org/people/profiles/anne-beaven
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2004 - 2007- University of North Carolina HospitalsResidency, Internal Medicine, 2000 - 2004
University of North Carolina at Chapel Hill School of MedicineClass of 2000
Certifications & Licensure
NC State Medical License 2003 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL Start of enrollment: 2016 Aug 26
- CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma Start of enrollment: 2019 Sep 17
- Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2023 Sep 08
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.Amrita Goyal, Daniel O'Leary, Bouthaina Dabaja, Wen-Kai Weng, Jasmine Zain
Transplantation and Cellular Therapy. 2024-11-01 - 5 citationsAnti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30lymphoma: a phase 1 study.Natalie S Grover, George Hucks, Marcie L Riches, Anastasia Ivanova, Dominic T Moore
The Lancet. Haematology. 2024-05-01 - T-cell lymphoma: the CAR-T revolution is coming.Natalie S Grover, Anne W Beaven
Blood. 2024-03-28
Abstracts/Posters
- High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant _ a Single Center ...Anne Beaven, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin LymphomaAnne Beaven, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
'Nursing Is Dangerous': What We Heard This WeekJune 19th, 2020
Stand up to Cancer Dream Team Tackles T-cell Lymphoma, Focused on CAR-Based StrategiesJanuary 28th, 2019
NCCN Awards Grants to Three Researchers to Investigate Volasertib in Hematologic MalignanciesFebruary 10th, 2016
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
